Therapeutic Asset Ratings

368 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
DISTILLED VINEGAR Pancreatic Neoplasm	Peking Union Medical College Hospital	N/A	D (26)
Exenatide Pancreatic Neoplasm	AstraZeneca		D (26)
Fingolimod Pancreatic Cancer	Institut du Cancer de Montpellier - Val d'Aurelle	N/A	D (26)
Glatiramer Pancreatic Cancer	Institut du Cancer de Montpellier - Val d'Aurelle	N/A	D (26)
HUMAN PERIPHERAL BLOOD LEUKOCYTES Pancreatic Neoplasm	A2 Biotherapeutics Inc.		D (26)
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER Pancreatic Cancer	Institut du Cancer de Montpellier - Val d'Aurelle	N/A	D (26)
Inkt Cells Pancreatic Cancer	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	N/A	D (26)
ms-20 Pancreatic Neoplasm	National Taiwan University Hospital	N/A	D (26)
MSLN-CART Pancreatic Neoplasm	Chinese University of Hong Kong	N/A	D (26)
Natalizumab Pancreatic Cancer	Institut du Cancer de Montpellier - Val d'Aurelle	N/A	D (26)
Secretin Pancreatic Neoplasm	Charles University, Czech Republic	N/A	D (26)
Teriflunomide Pancreatic Cancer	Institut du Cancer de Montpellier - Val d'Aurelle	N/A	D (26)
Trastuzumab Deruxtecan Pancreatic Neoplasm	AstraZeneca		D (26)
xh001 Pancreatic Neoplasm	Peking Union Medical College Hospital	N/A	D (26)
Shouhui Tongbian Capsules Pancreatic Neoplasm	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	P4	NR (0)
Fg-M108 Pancreatic Neoplasm	FutureGen Biopharmaceutical (Beijing) Co., Ltd	P3	NR (0)
ano31905 Pancreatic Neoplasm	Anova Innovation Limited	P1/2	NR (0)
ef-009 Pancreatic Neoplasm	Everfront Biotech Co., Ltd.	P1/2	NR (0)

Showing 351 to 368 of 368 assets

PreviousPage 15 of 15Next